Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.4000
-0.0218 (-5.17%)
At close: Aug 13, 2025, 4:00 PM
0.3900
-0.0100 (-2.50%)
Pre-market: Aug 14, 2025, 9:20 AM EDT
Incannex Healthcare Revenue
Incannex Healthcare had revenue of $98.00K in the twelve months ending March 31, 2025. In the fiscal year ending June 30, 2024, Incannex Healthcare had annual revenue of $12.00K.
Revenue (ttm)
$98.00K
Revenue Growth
n/a
P/S Ratio
73.22
Revenue / Employee
$10,889
Employees
9
Market Cap
37.48M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IXHL News
- 6 days ago - Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea - GlobeNewsWire
- 14 days ago - Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term - GlobeNewsWire
- 14 days ago - Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial - Benzinga
- 15 days ago - Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X - GlobeNewsWire
- 20 days ago - Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo - GlobeNewsWire
- 7 weeks ago - Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch - GlobeNewsWire
- 2 months ago - Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X - GlobeNewsWire
- 2 months ago - Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy - GlobeNewsWire